查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
憩室炎治疗的全球市场 - 2022年～2029年
市场调查报告书
商品编码
1077264

憩室炎治疗的全球市场 - 2022年～2029年

Global Diverticulitis Disease Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告提供全球憩室炎治疗市场相关调查，提供市场概要，以及各类型，不同治疗，各给药途径，各流通管道，各地区趋势，竞争情形，及加入此市场的主要企业简介等资讯。

目录

第1章 调查手法和范围

第2章 市场定义和概要

第3章 摘要整理

  • 各类型，市场明细
  • 不同治疗，市场明细
  • 各给药途径，市场明细
  • 各流通管道，市场明细
  • 各地区，市场明细

第4章 市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 影响分析

第5章 产业分析

  • 供应链分析
  • 价格分析
  • 未满足需求

第6章 COVID-19分析

第7章 各类型

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各类型
    • 市场魅力指数，各类型
  • 憩室症
  • 憩室炎
  • 其他

第8章 不同治疗

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、不同治疗
    • 市场魅力指数，不同治疗
  • 投药
    • 甲硝唑（Flagyl）
    • 甲氧芐啶-磺胺甲噁唑（Bactrim）
    • 环丙沙星（Cipro）
    • 克拉维酸（Augmentin）
    • 其他
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 手术
  • 食物纤维
  • 其他

第9章 各给药途径

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各给药途径
    • 市场魅力指数，各给药途径
  • 口服
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 静脉内

第10章 各流通管道

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各流通管道
    • 市场魅力指数，各流通管道
  • 院内药局
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 零售药局
  • 线上药局
  • 其他

第11章 各地区

  • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)，各地区
    • 市场魅力指数，各地区
  • 北美
  • 欧洲
  • 南美
  • 亚太地区
  • 中东·非洲

第12章 竞争情形

  • 主要的发展与策略
  • 企业占有率分析
  • 产品的基准
  • 值得注意的主要企业的清单

第13章 企业简介

  • Pfizer Inc.
  • G.D. Searle LLC
  • Teva Pharmaceuticals USA, Inc.
  • B. Braun Medical Inc.
  • GlaxoSmithKline, Inc.
  • Bayer HealthCare Pharmaceuticals Inc.
  • Hoffmann-La Roche Inc.
  • Hikma Pharmaceuticals USA Inc.

第14章 全球憩室炎治疗市场-DataM

简介目录
Product Code: DMPH5061

Market Overview

The global diverticulitis disease treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Diverticulitis is the infection or inflammation of pouches that occurs in the intestines. These pouches aren't usually harmless. They might appear in the intestines at any time. Diverticulosis is the medical term for having them. Mild diverticulitis can be treated with rest, changes in your diet and antibiotics. Severe or recurring diverticulitis may require surgery.

Market Dynamics

New guidelines for treating uncomplicated acute diverticulitis are expected to drive market growth.

Nonantibiotic therapy is currently considered a valid technique for uncomplicated acute diverticulitis by recent guidelines from associations worldwide, including the American Society of Colorectal Surgeons. CT scan findings must be compatible with uncomplicated acute diverticulitis, and patients must not show signs of sepsis, according to clinical practice guidelines for the treatment of left-sided colonic diverticulitis (2020), the Second International Symposium on Diverticular Disease, held in Rome in 2016, and the 2020 WSES guidelines. Immunocompetent patients with simple diverticulitis who show no symptoms of systemic inflammation should not be treated with antibiotics, according to the WSES. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Lack of patient awareness in developing countries, stringent FDA guidelines for the approval of the latest treatment and side effects associated with the drugs are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Patients delayed critical therapy for diverticulitis during the early stages of the COVID-19 epidemic, resulting in more severe disease and death. During the early surge, patients who needed surgery urgently/emergently had extreme conditions and stayed longer than expected. Patients who had their planned procedures postponed were more likely to be readmitted to the hospital and require urgent or emergency surgery. Therefore, understanding the impact of COVID-19's early surgeon diverticulitis outcomes may help us better prepare for future surges, improve outcomes, and identify patients who may be able to avoid surgery. Thus, the above statements affected the market, which is expected to boost in the forecast period.

Segment Analysis

Medication segment is expected to hold the largest market share in diverticulitis disease treatment market

The medication segment is expected to dominate in 2021. The segment is further sub-segmented into antibiotic dugs. Besides, the segment benefits because antibiotics are utilized to treat infections that can occur in acute diverticulitis. For instance, Metronidazole (Flagyl), Trimethoprim-sulfamethoxazole (Bactrim), Ciprofloxacin (Cipro), Clavulanic acid (Augmentin) are some of the antibiotic drugs which are used in the treatment of acute diverticulitis. Therefore, it has increased the demand for drugs in diverticulitis disease treatment. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global diverticulitis disease treatment market

In 2021, North America accounted for the highest revenue share. The rising geriatric population, increasing prevalence of obesity and smoking, rising demand for technologically advanced treatment, and growing public awareness of health issues in the region are factors the market is expected to boost in the forecast period. For instance, Overeating and physical inactivity are the two most common causes of obesity. Obesity is influenced by genetics, metabolism, environment, behavior, and culture, among other factors. The U.S. adult obesity rate stands at 42.4 percent, the first time the national rate has passed the 40 percent mark and further evidence of the country's obesity crisis.

Moreover, being Overweight affects more than one-third of men (34.1%) and one-quarter of women (27.5%). Obesity affects nearly half of all adults (42.4%). (including severe obesity). Severe obesity affects about one in every eleven persons (9.2%). The percentage of overweight men (34.1%) is higher than overweight women (33.4%). (27.5 percent ). Demand for services from the Weight Loss Services business is predicted to rise as the prevalence of adult obesity rises. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the diverticulitis disease treatment market are Pfizer Inc., G.D. Searle LLC, Teva Pharmaceuticals USA, Inc., B. Braun Medical Inc., GlaxoSmithKline, Inc., Bayer HealthCare Pharmaceuticals Inc., Hoffmann-La Roche Inc., Hikma Pharmaceuticals USA Inc.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its drugs and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

­Product Portfolio:

Flagyl Oral Formulation(metronidazole oral formulation): Metronidazole Oral Suspension is indicated in the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected as the pathogen.

Why Purchase the Report?

Visualize the composition of the diverticulitis disease treatment market segmentation by type, treatment, route of administration, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in diverticulitis disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of diverticulitis disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global diverticulitis disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Treatment
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. New guidelines for treating uncomplicated acute diverticulitis are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Diverticulosis
  • 7.3. Diverticulitis
  • 7.4. Others

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment Segment
  • 8.2. Medication*
    • 8.2.1. Metronidazole (Flagyl)
    • 8.2.2. Trimethoprim-sulfamethoxazole (Bactrim)
    • 8.2.3. Ciprofloxacin (Cipro)
    • 8.2.4. Clavulanic acid (Augmentin)
    • 8.2.5. Others
    • 8.2.6. Introduction
    • 8.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Surgery
  • 8.4. Dietary Fiber
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Intravenous

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacy*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Pfizer Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. G.D. Searle LLC
  • 13.3. Teva Pharmaceuticals USA, Inc.
  • 13.4. B. Braun Medical Inc.
  • 13.5. GlaxoSmithKline, Inc.
  • 13.6. Bayer HealthCare Pharmaceuticals Inc.
  • 13.7. Hoffmann-La Roche Inc.
  • 13.8. Hikma Pharmaceuticals USA Inc.

LIST NOT EXHAUSTIVE

14. Global Diverticulitis Disease Treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us